Soleno Therapeutics Inc.

SLNO:NASDAQ

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

Streetwise - Soleno Therapeutics Inc. Ownership Overview*

Soleno Therapeutics Inc. (SLNO:NASDAQ)

*Share Structure as of 6/28/2023